Caris Life Sciences (CAI) director Lloyd Minor receives 13,192-share stock award

Rhea-AI Filing Summary

Minor Lloyd reported acquisition or exercise transactions in this Form 4 filing.

Caris Life Sciences, Inc. reported that director Lloyd Minor received a grant of 13,192 shares of Common Stock in the form of restricted stock units on 2026-08-14 at a stated price of $0.00 per share. These restricted stock units vest in accordance with the applicable grant agreement. Following this award, Minor directly holds 31,813 shares of the company’s Common Stock.

Insider Trade Summary

Net Buyer: 13,192 shares

Net Buy 1 txn

Insider Minor Lloyd

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	13,192	$0.00	$0.00

Holdings After Transaction: Common Stock — 31,813 shares (Direct)

Footnotes (1)

1. F1. Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Key Figures

Shares granted: 13,192 shares Grant price: $0.00 per share Shares owned after: 31,813 shares +1 more

4 metrics

Shares granted 13,192 shares Restricted stock unit award on 2026-08-14

Grant price $0.00 per share Stated price for RSU award

Shares owned after 31,813 shares Direct Common Stock holdings after award

Transactions acquiring 1 transaction Single award transaction reported in Form 4

Key Terms

restricted stock units, vest, grant agreement

3 terms

restricted stock units financial

"Represents an award of restricted stock units which vest in accordance"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vest financial

"restricted stock units which vest in accordance with the applicable grant"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

grant agreement financial

"units which vest in accordance with the applicable grant agreement"

FAQ

What did Caris Life Sciences (CAI) director Lloyd Minor acquire in this Form 4?

Lloyd Minor received 13,192 shares of Caris Life Sciences Common Stock as a restricted stock unit award on 2026-08-14, bringing his total direct holdings to 31,813 shares.

At what price were the 13,192 Caris Life Sciences (CAI) shares granted to Lloyd Minor?

The 13,192 shares were granted at a stated price of $0.00 per share, reflecting a compensation-related award rather than an open-market purchase, as indicated in the Form 4 details.

How many Caris Life Sciences (CAI) shares does Lloyd Minor own after this transaction?

After the restricted stock unit award, Lloyd Minor directly holds 31,813 shares of Caris Life Sciences Common Stock, as reported in the Form 4 following the 13,192-share grant on 2026-08-14.

Do the Caris Life Sciences (CAI) restricted stock units granted to Lloyd Minor vest immediately?

No. The filing states the award is of restricted stock units that vest in accordance with the applicable grant agreement, meaning vesting occurs over time or upon conditions defined in that agreement.

Is Lloyd Minor’s Caris Life Sciences (CAI) share ownership direct or indirect after this award?

The Form 4 reports the post-transaction holdings of 31,813 shares as direct ownership, indicating the shares are held in Lloyd Minor’s own name rather than through an intermediary entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/14/2026 - 05:43 PM Accepted by SEC EDGAR 08/14/2026 - 05:42 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Minor Lloyd

(Last) (First) (Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING TEXAS 75039

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2026		A		13,192(1)	A	$0	31,813	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Remarks:

	/s/ J. Russel Denton, Attorney-in-Fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)